Smooth muscle cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy

Journal of Clinical Investigation

Volumn 113, Issue 5, 2004, Pages 668-675

  Wheeler, Matthew T ^a   Allikian, Michael J ^a   Heydemann, Ahlke ^a   Hadhazy, Michele ^a   Zarnegar, Sara ^a   McNally, Elizabeth M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE SYNTHASE INHIBITOR; SARCOGLYCAN; COMPLEMENTARY DNA; CYTOSKELETON PROTEIN; MEMBRANE PROTEIN; NITRIC OXIDE;

ALLELE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CELL DEGENERATION; CORONARY ARTERY; GENE MUTATION; HEART MUSCLE CELL; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; TISSUE INJURY; TISSUE OXYGENATION; TRANSGENE; VASCULARIZATION; VASOSPASM; ANIMAL; AUDIOVISUAL EQUIPMENT; BIOLOGICAL MODEL; C57BL MOUSE; CYTOLOGY; FIBROSIS; FLUORESCENCE MICROSCOPY; GENETICS; GENOTYPE; HEART MUSCLE; IMMUNOBLOTTING; MEMBRANE; METABOLISM; MICROCIRCULATION; MUSCLE SPASM; MUTATION; NECROSIS; PATHOLOGY; PERMEABILITY; PHYSIOLOGY; VASCULAR DISEASE;

ALLELES; ANIMALS; CARDIOMYOPATHIES; CYTOSKELETAL PROTEINS; DNA, COMPLEMENTARY; FIBROSIS; GENOTYPE; IMMUNOBLOTTING; MEMBRANE GLYCOPROTEINS; MEMBRANES; MICE; MICE, INBRED C57BL; MICROCIRCULATION; MICROSCOPY, FLUORESCENCE; MODELS, ANATOMIC; MODELS, GENETIC; MUTATION; MYOCARDIUM; MYOCYTES, CARDIAC; MYOCYTES, SMOOTH MUSCLE; NECROSIS; NITRIC OXIDE; PERMEABILITY; SARCOGLYCANS; SPASM; TRANSGENES; VASCULAR DISEASES;

EID: 1842434556     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200420410     Document Type: Article

References (34)

1. Hack, A.A., Groh, M.E., and McNally, E.M. 2000. Sarcoglycans in muscular dystrophy. Microsc. Res. Tech. 48:167-180.
2. Ozawa, E., Noguchi, S., Mizuno, Y., Hagiwara, Y., and Yoshida, M. 1998. From dystrophinopathy to sarcoglycanopathy: evolution of a concept of muscular dystrophy. Muscle Nerve. 21:421-438.
3. Chan, Y.M., Bonnemann, C.G., Lidov, H.G., and Kunkel, L.M. 1998. Molecular organization of sarcoglycan complex in mouse myotubes in culture. J. Cell Biol. 143:2033-2044.
4. Yoshida, M., et al. 2000. Biochemical evidence for association of dystrobrevin with the sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy. Hum. Mol. Genet. 9:1033-1040.
5. Blake, D.J., Weir, A., Newey, S.E., and Davies, K.E. 2002. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 82:291-329.
6. Durbeej, M., et al. 2000. Disruption of the β-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E. Mol. Cell. 5:141-151.
7. Coral-Vazquez, R., et al. 1999. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell. 98:465-474.
8. Hack, A.A., et al. 2000. Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex. J. Cell Sci. 113:2535-2544.
9. Duclos, F., et al. 1998. Progressive muscular dystrophy in α-sarcoglycan-deficient mice. J. Cell Biol. 142:1461-1471.
10. Cohn, R.D., et al. 2001. Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex. J. Clin. Invest. 107:R1-R7.
11. Liu, L.A., and Engvall, E. 1999. Sarcoglycan isoforms in skeletal muscle. J. Biol. Chem. 274:38171-38176.
12. Wheeler, M.T., Zarnegar, S., and McNally, E.M. 2002. ζ-sarcoglycan, a novel component of the sarcoglycan complex, is reduced in muscular dystrophy. Hum. Mol. Genet. 11:2147-2154.
13. Straub, V., et al. 1999. ε-sarcoglycan replaces alpha-sarcoglycan in smooth muscle to form a unique dystrophin-glycoprotein complex. J. Biol. Chem. 274:27989-27996.
14. Hack, A.A., et al. 1998. γ-sarcoglycan deficiency leads to muscle membrane defects and apoptosis independent of dystrophin. J. Cell Biol. 142:1279-1287.
15. Subramaniam, A., et al. 1991. Tissue-specific regulation of the α-myosin heavy chain gene promoter in transgenic mice. J. Biol. Chem. 266:24613-24620.
16. Solway, J., et al. 1995. Structure and expression of a smooth muscle cell-specific gene, SM22α. J. Biol. Chem. 270:13460-13469.
17. Heydemann, A., Hadhazy, M.R., Huber, J.M., Wheeler, M.T., and McNally, E.M. 2004. Functional nitric oxide mislocalization in cardiomyopathy. J. Mol. Cell. Cardiol. In press.
18. Zhu, X., et al. 2001. Overexpression of γ-sarcoglycan induces severe muscular dystrophy. Implications for the regulation of sarcoglycan assembly. J. Biol. Chem. 276:21785-21790.
19. Zhu, X., Hadhazy, M., Wehling, M., Tidball, J.G., and McNally, E.M. 2000. Dominant negative myostatin produces hypertrophy without hyperplasia in muscle. FEBS Lett. 474:71-75.
20. McNally, E.M., et al. 1996. Mutations that disrupt the carboxyl-terminus of γ-sarcoglycan cause muscular dystrophy. Hum. Mol. Genet. 5:1841-1847.
21. Bonnemann, C.G., et al. 1996. Genomic screening for β-sarcoglycan gene mutations: missense mutations may cause severe limb-girdle muscular dystrophy type 2E (LGMD 2E). Hum. Mol. Genet. 5:1953-1961.
22. KATP channels. J. Clin. Invest. 110:203-208. doi:10.1172/JCI200215672.
23. Factor, S.M., Minase, T., Cho, S., Dominitz, R., and Sonnenblick, E.H. 1982. Microvascular spasm in the cardiomyopathic Syrian hamster: a preventable cause of focal myocardial necrosis. Circulation. 66:342-354.
24. Pepine, C.J. 1995. Effect of calcium antagonists in variant or Prinzmetal angina. Can. J. Cardiol. 11:952-956.
25. Lanza, G.A., and Maseri, A. 2000. Coronary artery spasm. Curr. Treat. Options Cardiovasc. Med. 2:83-90.
26. Politano, L., et al. 2001. Evaluation of cardiac and respiratory involvement in sarcoglycanopathies. Neuromuscul. Disord. 11:178-185.
27. Barresi, R., et al. 2000. Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by β sarcoglycan mutations. J. Med. Genet. 37:102-107.
28. van der Kooi, A.J., et al. 1998. The heart in limb girdle muscular dystrophy. Heart. 79:73-77.
29. Tsubata, S., et al. 2000. Mutations in the human δ-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J. Clin. Invest. 106:655-662.
30. Ludmer, P.L., et al. 1986. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 315:1046-1051.
31. Dzau, V.J., and Cooke, J.P. 1996. Pathophysiology of vasospasm. In Vascular medicine: a textbook of vascular biology and diseases. J. Loscalzo, M.A. Creager, and V.J. Dzau, editors. Lippincott, Williams & Wilkins. Boston, Massachusetts, USA. 371-389.
32. Nigro, V., et al. 1997. Identification of the Syrian hamster cardiomyopathy gene. Hum. Mol. Genet. 6:601-607.
33. Krams, R., et al. 1998. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation. 97:230-233.
34. Maron, B.J., Wolfson, J.K., Epstein, S.E., and Roberts, W.C. 1986. Intramural ("smallvessel") coronary artery disease in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 8:545-557.